Inogen
2 activist/short documents on this target.
Timeline
2019-02-15
Citron Research · full deck
Inogen's growth is built on a reseller network that lies to elderly customers about Medicare coverage to force cash sales — competition and oversight will collapse margins to a $46 stock.
N4 V2
2019-02-25
Muddy Waters · research note
INGN's growth narrative rests on an inflated $3-4B TAM that Medicare data contradicts; under a realistic 1.3M-user market, peak unit sales arrive this year or next.
N4 V1